We are live on ! Find out more
ADVM

Adverum Biotechnologies
ADVM

Delisted

ADVM was delisted on the 8th of December, 2025.

Back to rankings

141 hedge funds and large institutions have $1.69B invested in Adverum Biotechnologies in 2020 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 60 increasing their positions, 38 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

211% more call options, than puts

Call options by funds: $15.9M | Put options by funds: $5.1M

114% more capital invested

Capital invested by funds: $790M → $1.69B (+$899M)

107% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 14

58% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 38

14% more funds holding in top 10

Funds holding in top 10: 7 → 8 (+1)

12% more funds holding

Funds holding: 126 → 141 (+15)

0.07% less ownership

Funds ownership: 10.14% → 10.07% (-0.07%)

Holders
141
Holders Change
+15
Holders Change %
+11.9%
% of All Funds
2.89%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.16%
New
29
Increased
60
Reduced
38
Closed
14
Calls
$15.9M
Puts
$5.1M
Net Calls
+$10.8M
Net Calls Change
-$273K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$22M
2
BlackRock
BlackRock
New York
+$15.3M
3
CC
Casdin Capital
New York
+$13.1M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$11.8M
5
RCM
RA Capital Management
Massachusetts
+$9.37M

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$25.8M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$23M
3
DM
Deerfield Management
New York
-$22M
4
UBS Group
UBS Group
Switzerland
-$14.4M
5
VA
VR Adviser
New York
-$9.71M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$12.2M -$8.88M -50,120 -46%
Citigroup
27
Citigroup
New York
$10.6M +$7.65M +43,171 +584%
Adage Capital Partners
28
Adage Capital Partners
Massachusetts
$10.4M -$23M -130,000 -72%
RPAM
29
Rhenman & Partners Asset Management
Sweden
$10.4M -$886K -5,000 -9%
SFSIG
30
San Francisco Sentry Investment Group
California
$10M – – –
FLAM
31
First Light Asset Management
Minnesota
$9.81M +$4.03M +22,750 +94%
Charles Schwab
32
Charles Schwab
California
$9.45M +$1.19M +6,724 +17%
Invesco
33
Invesco
Georgia
$8.54M +$256K +1,443 +4%
Bank of America
34
Bank of America
North Carolina
$8.29M +$6.37M +35,942 +961%
N
35
Nuveen
North Carolina
$7.43M +$1.92M +10,840 +44%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$6.84M +$1.22M +6,907 +27%
Assenagon Asset Management
37
Assenagon Asset Management
Luxembourg
$6.69M +$5.67M +32,022 New
Fidelity Investments
38
Fidelity Investments
Massachusetts
$6.18M +$2.15M +12,113 +69%
JP Morgan Chase
39
JP Morgan Chase
New York
$6.14M +$1.42M +8,027 +38%
Barclays
40
Barclays
United Kingdom
$5.91M +$250K +1,414 +5%
Millennium Management
41
Millennium Management
New York
$5.7M -$1.86M -10,505 -28%
Allianz Asset Management
42
Allianz Asset Management
Germany
$5M -$1.11M -6,260 -21%
CS
43
Candriam SCA
Luxembourg
$4.77M +$506K +2,858 +14%
Federated Hermes
44
Federated Hermes
Pennsylvania
$4.75M +$4.03M +22,769 New
SCM
45
Soleus Capital Management
Connecticut
$4.57M -$1.69M -9,518 -30%
California Public Employees Retirement System
46
California Public Employees Retirement System
California
$3.46M +$695K +3,925 +31%
CAC
47
Cowen and Company
New York
$3.35M -$1.03M -5,840 -27%
BCM
48
Burrage Capital Management
Massachusetts
$3.26M – – –
Swiss National Bank
49
Swiss National Bank
Switzerland
$2.8M +$337K +1,900 +17%
Victory Capital Management
50
Victory Capital Management
Texas
$2.73M -$25.8M -145,477 -92%
1
2
3 4 5

ADVM Hedge Fund Activity: Q2 2020 in Review

141 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q2 2020, worth a combined $1.69B — up 114% from $790M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ADVM positions and 14 closed out — a net gain of 15 holders — while 60 added to existing stakes and 38 trimmed.

The largest buyer was Wellington Management Group, opening a new position worth an estimated $22M. The largest seller was Victory Capital Management, cutting an estimated $25.8M.

  • 141 institutional investors held Adverum Biotechnologies (ADVM) as of Q2 2020, up from 126 in Q1 2020.
  • Funds reported $1.69B of Adverum Biotechnologies stock for Q2 2020, up 114% quarter-over-quarter.
  • 29 funds opened new Adverum Biotechnologies positions in Q2 2020 and 14 closed out, a net change of +15 holders.
  • The largest Adverum Biotechnologies buyer in Q2 2020 was Wellington Management Group, an estimated $22M added.
  • The largest Adverum Biotechnologies seller in Q2 2020 was Victory Capital Management, an estimated $25.8M sold.

Based on aggregated 13F filings for Q2 2020.